このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions

A Phase 1b, Open-label, Multicenter Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Subretinal Dose of ASP2020 in Participants With Macular Dystrophies With a Stargardt-type Clinical Presentation

Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This leads to loss of central vision, which can make it harder to read, recognize faces or see fine details. What's seen out of the corner of the eye (peripheral vision) is mostly unaffected. Stargardt disease (STGD) is a type of macular dystrophy which is caused by 1 faulty gene (ABCA4). Vision loss most typically begins in childhood or teenage years but may also develop in adulthood. As well as STGD, there are other macular dystrophies that look very similar to STGD and are called STGD-like macular dystrophies. These are caused by many other different genes. Together, STGD and STGD-like conditions can be called STGD-type macular dystrophies.

This is an early development study of ASP2020 in adults, teenagers, and children with STGD-type macular dystrophies. ASP2020 are human stem cells which have been changed into cells found in the macula. In this study ASP2020 will be given to people for the first time. The main aim of the study is to check the safety of ASP2020 and how well people tolerate it. Other aims are to learn if people have an immune reaction to ASP2020, and if there are signs that the stem cells replace damaged cells in the retina, and vision improves for people with STGD-type macular dystrophies.

ASP2020 will be given as a single injection into the eye, under the retina. This requires a surgical procedure where the person is put to sleep by a general anesthetic. At the end of surgery, a steroid will be injected into the eye to reduce any swelling.

The study has 2 parts. In Part 1, different small groups will receive a lower to higher dose of ASP2020. This is done to find a suitable dose to use in Part 2. The adults will receive the lower dose and higher dose before the teenagers. There will be a 6-month gap between the last adult receiving the lower dose of ASP2020 and the first teenager receiving the same lower dose. This will also happen for the last adult receiving the higher dose of ASP2020 and the first teenager receiving the higher dose of ASP2020. Any medical problems will be recorded for each dose in each group. Children will not receive ASP2020 in Part 1.

In Part 2, different groups of adults, teenagers and children will receive the most suitable dose of ASP2020 worked out from Part 1.

People will be in the study for about 1 year and they will visit the clinic several times. In both parts of the study, safety checks will be done at each visit, and the study doctors will continue to check for any medical problems throughout the study. Various eye tests and eye imaging will be done throughout the study. Blood tests will also be done at some of the visits during the study.

調査の概要

研究の種類

介入

入学 (推定)

30

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Arizona
      • Phoenix、Arizona、アメリカ、85020
        • 募集
        • Associated Retina Consultants
    • Ohio
      • Cincinnati、Ohio、アメリカ、45242
        • 募集
        • Cincinnati Eye Institute
    • Texas
      • Dallas、Texas、アメリカ、75231
        • 募集
        • Retina Foundation of Southwest

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Documented clinical diagnosis of macular dystrophy with a STGD-type clinical presentation and molecular confirmation, defined as either:

    • STGD: presence of biallelic (pathogenic or likely pathogenic) ABCA4 variants, or one definite disease-causing ABCA4 variant together with a typical phenotype consistent with STGD.
    • STGD-like macular dystrophy: presence of one or more pathogenic variants in a gene known to cause macular dystrophy, as appropriate for its expected inheritance mode.
  • Sufficiently clear ocular media and adequate pupillary dilation to allow for all imaging procedures.
  • Intraocular pressure (IOP) of ≤ 21 mmHg
  • Participant has a spherical equivalent refractive error between +8.00 D and -10.00 D.
  • BCVA ranging from 20/500 to 20/40 (equivalent to 15 to 70 ETDRS letters)

    • For participants in the > 20/80 to ≤ 20/40 BCVA range (moderate visual impairment [MVI]): presence of a visible definite or probable residual ellipsoid zone (EZ) on SD-OCT, and a total retinal SD-OCT central subfield thickness ≥ 150 micrometers (µm)
    • For participants in the ≥ 20/500 to ≤ 20/80 BCVA range (severe visual impairment): Presence of a residual ONL within the macular optical coherence tomography (OCT) scan area and Evidence of RPE disease/damage by means of SD-OCT (hypertransmission defect) and/or FAF imaging (questionably decreased autofluorescence/definitely decreased autofluorescence).

Exclusion Criteria:

  • Participant has a known history of significant systemic disease that could impact ocular health or confound study assessments, based on medical history or prior clinical documentation.
  • Participant has an autoimmune condition that requires treatment with immunomodulatory therapy and/or biologics that cause immunosuppression.
  • Participant has known diagnosis of diabetes mellitus with a documented glycated hemoglobin (HbA1c) value ≥ 7% 3 months prior to screening and based on available medical records.
  • Participant has a history or evidence of severe cardiac disease, cardiovascular or cerebrovascular disease, including a history of stroke within 12 months prior to screening.
  • Participant has any complicating systemic disease or active malignancy.
  • Participant has a known history of any systemic or metabolic condition, or physical examination finding that may significantly affect ocular health or interfere with the interpretation of study assessments.
  • Participant has presence of another known or suspected molecular diagnosis of macular or retinal disease that could confound interpretation of study outcomes, indicate a second concomitant retinal condition, or suggest a different etiology for the macular disease.
  • Participant has macular atrophy due to any cause other than a genetically or clinically confirmed diagnosis of STGD or STGD-like macular dystrophy.
  • Participant has evidence or history of choroidal neovascularization.
  • Participant has diagnosis of any form of uncontrolled glaucoma (for high-tension glaucoma IOP > 25 mmHg).
  • Participant has a history of steroid-induced IOP elevation or known steroid responder status.
  • Participant has and/or is receiving treatment for thyroid eye disease.
  • Participant has diabetic retinopathy in excess of mild nonproliferative diabetic retinopathy
  • Participant has any other disease(s) affecting the optic nerve.
  • Participant has a history of anterior or posterior uveitis and/or presence of intraocular inflammation (trace anterior chamber cell or flare), or history of idiopathic or autoimmune-associated uveitis in either eye.
  • Participant has media opacities impeding the visualization of the fundus and/or the reliable performance of the visual function tests required by the protocol.
  • Participant has aphakia.
  • Participant has a clinically significant epiretinal membrane or evidence of clinically significant vitreomacular traction syndrome.
  • Participant has any other disorders which could interfere with or confound visual acuity and other ocular assessments, including OCT or FAF.
  • Participant has history of any of the following procedures: posterior vitrectomy, retinal detachment surgery, glaucoma filtering surgery, glaucoma drainage device implantation, selective laser trabeculoplasty, full-thickness or partial- thickness corneal transplant.
  • Participant has had any intraocular surgery within 3 months of screening.
  • Participant has a history of intraocular metallic foreign bodies.
  • Participant has received any treatment including gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips, or any prior intravitreal treatment for any indication in either eye that may be considered to potentially interfere with the study participation or its conduct.
  • Participant has received within 1 month prior to screening or is receiving concomitant treatment with any ocular or systemic medication known to be toxic to the lens, retina, or optic nerve.
  • Participant has received any investigational therapy within 3 months prior to screening.
  • Participant has any condition, which makes the participant unsuitable for study participation.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Part 1 Dose Escalation: Adult - Low Dose
Adult participants will receive a single low dose of ASP2020 on Day 1, administered by subretinal injection as part of a surgical procedure, followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Subretinal Injection
実験的:Part 1 Dose Escalation: Adult - High Dose
Adult participants will receive a single high dose of ASP2020 on Day 1, administered by subretinal injection as part of a surgical procedure, followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Subretinal Injection
実験的:Part 1 Dose Escalation: Adolescent - Low Dose
Adolescent participants will receive single low dose of ASP2020 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Subretinal Injection
実験的:Part 1 Dose Escalation: Adolescent - High Dose
Adolescent participants will receive single high dose of ASP2020 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Subretinal Injection
実験的:Part 2 Dose Expansion: Adult with macular dystrophies
Adult participants will receive single optimal dose of ASP2020 established in part 1 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Subretinal Injection
実験的:Part 2 Dose Expansion: Pediatric with macular dystrophies
Pediatric participants will receive single optimal dose of ASP2020 established in part 1 by subretinal injection on Day 1 followed by triamcinolone acetonide as adjunct treatment by posterior sub-Tenon injection.
Subretinal Injection

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of participants with treatment-emergent adverse events (TEAEs)
時間枠:Up to 52 weeks

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

TEAEs are defined as an AE observed after administration of ASP2020 or pre-existing AE that worsen in severity or frequency following administration of ASP2020.

Up to 52 weeks
Number of participants with serious adverse events (SAEs)
時間枠:Up to 52 weeks
An SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other medically important events.
Up to 52 weeks
Number of participants with adverse events of special interest (AESIs)
時間枠:Up to 52 weeks

AESIs include, but are not limited to, the following:

  • Ectopic, excessive, or aberrant cell growth of ASP2020, including proliferative changes
  • Immune-mediated reactions, including unexpected or clinically significant inflammatory responses
  • Any new diagnosis of malignancy
  • Any clinically significant AEs possibly or definitely related to ASP2020
  • Clinically significant AEs related to the surgical administration procedure
Up to 52 weeks
Number of participants with greater than or equal to 15 letter loss in best corrected visual acuity (BCVA) from baseline
時間枠:Up to 52 weeks
BCVA will be measured from the Early Treatment of Diabetic Retinopathy Study (ETDRS) letters chart.
Up to 52 weeks
Number of participants with significant changes in vital signs from baseline
時間枠:Up to 52 weeks
Number of participants with significant changes in vital signs from baseline will be reported.
Up to 52 weeks
Number of participants with significant changes in laboratory values from baseline
時間枠:Up to 52 weeks
Number of participants with significant changes in laboratory values from baseline will be reported.
Up to 52 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Change from baseline in BCVA
時間枠:Baseline and week 26, 52 or Early Termination (ET) visit whichever occurs first
BCVA will be measured from the ETDRS letters chart.
Baseline and week 26, 52 or Early Termination (ET) visit whichever occurs first
Change from baseline in low luminance visual acuity (LLVA)
時間枠:Baseline and week 26, 52 or ET visit whichever occurs first
LLVA will be measured from the ETDRS letters chart.
Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in Minnesota Reading Acuity Chart (MNREAD) parameters
時間枠:Baseline and week 26, 52 or ET visit whichever occurs first
MNREAD evaluates near reading acuity, reading speed and critical print size.
Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in mesopic macular sensitivity
時間枠:Baseline and week 26, 52 or ET visit whichever occurs first
Mean sensitivity, point-wise sensitivity (PWS), scotomatous/non-seen point count) will be measured by mesopic microperimetry.
Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in central retinal thickness (CRT)
時間枠:Baseline and week 26, 52 or ET visit whichever occurs first
CRT will be measured by spectral- domain optical coherence tomography (SD-OCT).
Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in total photoreceptor thickness (TPT)
時間枠:Baseline and week 26, 52 or ET visit whichever occurs first
TPT will be measured by SD-OCT.
Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in ellipsoid zone (EZ) integrity
時間枠:Baseline and week 26, 52 or ET visit whichever occurs first
EZ integrity will be measured by SD- OCT.
Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in outer nuclear layer (ONL)
時間枠:Baseline and week 26, 52 or ET visit whichever occurs first
ONL will be measured by SD-OCT.
Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in retinal pigment epithelium (RPE) integrity
時間枠:Baseline and week 26, 52 or ET visit whichever occurs first
RPE structural integrity will be measured by SD-OCT.
Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in questionably decreased autofluorescence (QDAF)
時間枠:Baseline and week 26, 52 or ET visit whichever occurs first
QDAF will be measured with fundus autofluorescence (FAF).
Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in definitely decreased autofluorescence (DDAF)
時間枠:Baseline and week 26, 52 or ET visit whichever occurs first
DDAF will be measured with FAF.
Baseline and week 26, 52 or ET visit whichever occurs first
Change from baseline in anti-human leukocyte antigen (HLA) antibodies
時間枠:Baseline and week 4, 12 and 52 or ET visit whichever occurs first
Anti-HLA antibodies will be measured from the serum samples.
Baseline and week 4, 12 and 52 or ET visit whichever occurs first
Change from baseline in anti herpes simplex virus thymidine kinase (HSV- TK) antibodies
時間枠:Baseline and week 4, 12 and 52 or ET visit whichever occurs first
Anti HSV-TK antibodies will be measured from the serum samples.
Baseline and week 4, 12 and 52 or ET visit whichever occurs first
Change from baseline in cytokines
時間枠:Baseline and week 1, 4, 12 and 52 or ET visit whichever occurs first
Cytokines will be measured from the serum samples.
Baseline and week 1, 4, 12 and 52 or ET visit whichever occurs first

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Medical Lead、Astellas Institute for Regenerative Medicine

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年8月10日

一次修了 (推定)

2029年9月30日

研究の完了 (推定)

2029年9月30日

試験登録日

最初に提出

2026年7月15日

QC基準を満たした最初の提出物

2026年7月24日

最初の投稿 (実際)

2026年7月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月16日

QC基準を満たした最後の更新が送信されました

2026年9月15日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する